Peptide Decoding
New?New to peptides?Start here →
Decoding

HM17321 (LA-UCN2)_Dosage, benefits & legal status

Also known as HM17321, LA-UCN2

Published November 17, 2026

The non-incretin obesity bet: weight loss without the muscle loss, so far only as a design goal.

Weight lossLong-acting urocortin-2 analog (CRF2 receptor agonist)Investigational
DosePhase 1 dose levels have not been published
FrequencyNot disclosed
RouteInjected; the route is not stated in the documents read here
StatusInvestigational
CycledNot established

See how this dose compares across the library →

01

What is HM17321 (LA-UCN2)?

Plain language first. The technical label stays, but it never stands alone.

Overview

An early-stage obesity injection that works on a different target than Ozempic-style drugs, meant to protect muscle.

The technical version

HM17321 is a long-acting urocortin-2 analog agonist at corticotropin-releasing factor receptor 2, in phase 1 for obesity, licensed to Genentech in August 2026.

What it's used for

An investigational obesity peptide that works outside the GLP-1 pathway, aiming to spare lean mass.

02

How does HM17321 (LA-UCN2) work?

What it does in the body, and where.

Urocortin-2 is a natural 41-residue peptide in the corticotropin-releasing factor family. HM17321 is an engineered long-acting version of it, and the receptor it acts on is the whole point.

  1. 01
    It acts on CRF2, not on GLP-1
    Every approved obesity medicine works through incretin receptors. The developer describes HM17321 as a non-incretin mechanism acting on the corticotropin-releasing factor receptor 2, which is a different pathway entirely.
  2. 02
    The lean-mass claim is the reason anyone cares
    The licensing announcement describes it as a potential first-in-class treatment designed to promote weight loss and preserve lean body mass at the same time. That is a design intention. No human body-composition result has been published.
  3. 03
    Long-acting is an engineering change, not a mechanism
    The LA in LA-UCN2 is about how long it lasts in the body. Natural urocortin-2 is cleared quickly, which is why this site's urocortin-2 card describes a research compound given by infusion rather than a weekly injection.
  4. 04
    What is actually known
    A phase 1 study in healthy volunteers and people with obesity, and a very large licensing deal. Nothing about how much weight it takes off in people, or whether the muscle-sparing idea survives contact with human data.
Anatomical illustration highlighting the whole body
WHAT THIS COMPOUND ACTS ON:
CRF2
03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Chronic weight management, the licensed indicationInvestigational
  • Type 2 diabetes and cardiovascular disease, named in the licensing announcement as associated conditionsInvestigational
  • Preserving lean body mass during weight loss, which is the design goal and not a demonstrated human effectnone

The published record

Research index

0

Papers about HM17321 (LA-UCN2) · this compound only

Searched: HM17321, LA-UCN2.

1 papers tagged human · 0 not reviews or lab · 0 clinical trial publications

1 registered trials · none with posted results

Furthest stage reached: Phase 1, under way

Compare this against the whole library →

In animals0
In the lab0
Reviews0
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

HM17321 (LA-UCN2) vial rendering
Compound field notes

At a glance

Four things to know about HM17321 (LA-UCN2)

01

Evidence

Investigational

02

Category

Weight loss and metabolic

03

Common vial

Varies

04

Half-life

Not published

04

How much, and do you cycle it?

The range, and whether you take breaks.

Phase 1 dose levels have not been published, not disclosed. Not established No range

A phase 1 compound with no published dosing schedule. There is nothing to cycle because there is no established way to take it.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not publishedNo figure

No pharmacokinetic data has been published. Long-acting is in the compound's own development name, which implies a half-life engineered to support infrequent dosing, but no measured figure appears in anything read here. Natural urocortin-2 is cleared quickly, which is the problem the analog exists to solve.

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Enter the amount printed on your label.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: No dose can be given. The phase 1 study's dose levels have not been published, and no community convention exists for a compound that has never been outside a trial. The route is not stated in anything read here either.No range

Choose your mix

mL water—units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW0 / 100 units
07

How do you store it?

Before mixing, and after.

Nothing to store: it is not sold anywhere.

HM17321 (LA-UCN2) has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.
  • Not applicable: this is an investigational compound with no approved use and no published safety profile
  • Anyone outside a registered clinical trial, because there is no legitimate supply

Stop and get help

These are emergencies. Seek care.
  • Not applicable outside a clinical trial, where the protocol and the study doctor govern

Common effects

Expected, and usually mild.
  • None published.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is HM17321 (LA-UCN2) approved?

And where the numbers on this page come from.

No. HM17321 (LA-UCN2) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

Guides for this compound

Sources

  • Hanmi Pharm, Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy(2026)
    The developer's own announcement, which is the primary document for everything on this card. Hanmi entered an exclusive licensing agreement with Genentech, a member of the Roche Group, for the development, manufacturing and commercialization of HM17321 (UCN2) for obesity and associated conditions including type 2 diabetes and cardiovascular disease, worldwide excluding South Korea. It describes HM17321 as a proprietary urocortin-2 analog with a non-incretin mechanism of action and a potential first-in-class treatment designed to promote weight loss and preserve lean body mass at the same time. Total deal value up to 2.3 billion dollars including the upfront payment, milestones and tiered royalties on net sales.
  • Dailypharm Korea, Hanmi licenses obesity drug candidate to Genentech(2026)
    Trade reporting that puts a number on the upfront and on the handover. The deal is reported at 2.305 billion dollars in total including a 190 million dollar upfront payment, with Hanmi completing the ongoing phase 1 study before development responsibility transfers to Genentech from phase 2 onward.

Beyond these, 1 records are indexed for this compound. Browse the records